News & Updates

Melinta Therapeutics enters into merger agreement with Tetraphase Pharmaceuticals

Melinta Therapeutics, Inc., a commercial-stage antibiotics company, announced that on June 4, 2020, it entered into a definitive merger agreement with Tetraphase Pharmaceuticals, Inc. (“Tetraphase”) pursuant to which Melinta would acquire Tetraphase, through a tender offer, for an aggregate of $39.0 million in cash, plus an additional $16.0 million in cash potentially payable under contingent value rights (“CVRs”) to be issued in the proposed acquisition.  Closing of the transaction is subject to specified closing conditions and is expected to occur…